An antibody against Siglec-15 promotes bone formation and fracture healing by increasing TRAP⁺ mononuclear cells and PDGF-BB secretion

Abstract

Osteoporosis (OP) is a common age-related disease characterized by a deterioration of bone mass and structure that predisposes patients to fragility fractures. Pharmaceutical therapies that promote anabolic bone formation in OP patients and OP-induced fracture are needed. We investigated whether a neutralizing antibody against Siglec-15 can simultaneously inhibit bone resorption and stimulate bone formation. We found that the multinucleation of osteoclasts was inhibited in SIGLEC-15 conditional knockout mice and mice undergoing Siglec-15 neutralizing antibody treatment. The secretion of platelet-derived growth factor-BB (PDGF-BB), the number of tartrate-resistant acid phosphatase-positive (TRAP⁺) mononuclear cells, and bone formation were significantly increased in the SIGLEC-15 conditional knockout mice and antibody-treated mice. The anabolic effect of the Siglec-15 neutralizing antibody on bone formation was blunted in mice with Pdgfb deleted in TRAP⁺ cells. These findings showed that the anabolic effect of the Siglec-15 neutralizing antibody was mediated by elevating PDGF-BB production of TRAP⁺ mononuclear cells. To test the therapeutic potential of the Siglec-15 neutralizing antibody, we injected the antibody in an ovariectomy-induced osteoporotic mouse model, which mimics postmenopausal osteoporosis in women, and in two fracture healing models because fracture is the most serious health consequence of osteoporosis. The Siglec-15 neutralizing antibody effectively reduced bone resorption and stimulated bone formation in estrogen deficiency-induced osteoporosis. Of note, the Siglec-15 neutralizing antibody promoted intramembranous and endochondral ossification at the damaged area of cortical bone in fracture healing mouse models. Thus, the Siglec-15 neutralizing antibody shows significant translational potential as a novel therapy for OP and bone fracture.

References

[1] Crocker PR, Paulson JC, Varki A. Siglecs and their roles in the immune system. Nat. Rev. Immunol., 2007, 7: 255-266

[2] Kameda Y et al. Siglec-15 regulates osteoclast differentiation by modulating RANKL-induced phosphatidylinositol 3-kinase/Akt and Erk pathways in association with signaling Adaptor DAP12. J. Bone Miner. Res, 2013, 28: 2463-2475

[3] Stuible M et al. Mechanism and function of monoclonal antibodies targeting siglec-15 for therapeutic inhibition of osteoclastic bone resorption. J. Biol. Chem., 2014, 289: 6498-6512

[4] Kameda Y et al. Siglec-15 is a potential therapeutic target for postmenopausal osteoporosis. Bone, 2015, 71: 217-226

[5] Ishida-Kitagawa N et al. Siglec-15 protein regulates formation of functional osteoclasts in concert with DNAX-activating protein of 12kD (DAP12). J. Biol. Chem., 2012, 287: 17493-17502

[6] Humphrey MB et al. The signaling adapter protein DAP12 regulates multinucleation during osteoclast development. J. Bone Miner. Res, 2004, 19: 224-234

[7] Wright NC et al. The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. J. Bone Miner. Res, 2014, 29: 2520-2526

[8] Kennel KA, Drake MT. Adverse effects of bisphosphonates: implications for osteoporosis management. Mayo Clin. Proc., 2009, 84: 632-637

[9] Abrahamsen B. Adverse effects of bisphosphonates. Calcif. Tissue Int., 2010, 86: 421-435

[10] Ding N et al. Alendronate induces osteoclast precursor apoptosis via peroxisomal dysfunction mediated ER stress. J. Cell Physiol., 2018, 233: 7415-7423

[11] Watts NB, Diab DL. Long-term use of bisphosphonates in osteoporosis. J. Clin. Endocrinol. Metab., 2010, 95: 1555-1565

[12] Morley P, Whitfield JF, Willick GE. Parathyroid hormone: an anabolic treatment for osteoporosis. Curr. Pharm. Des., 2001, 7: 671-687

[13] Cranney A et al. Parathyroid hormone for the treatment of osteoporosis: a systematic review. CMAJ, 2006, 175: 52-59

[14] Anastasilakis AD, Polyzos SA, Makras P. Therapy of endocrine disease: denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis. Eur. J. Endocrinol., 2018, 179: R31-R45

[15] Khosla S, Hofbauer LC. Osteoporosis treatment: recent developments and ongoing challenges. Lancet Diabetes Endocrinol., 2017, 5: 898-907

[16] Leder BZ. Optimizing sequential and combined anabolic and antiresorptive osteoporosis therapy. J. Bone Miner. Res., 2018, 2: 62-68

[17] Lou S et al. Combination therapy with parathyroid hormone analogs and antiresorptive agents for osteoporosis: a systematic review and meta-analysis of randomized controlled trials. Osteoporos. Int., 2019, 30: 59-70

[18] Shen L et al. Parathyroid hormone versus bisphosphonate treatment on bone mineral density in osteoporosis therapy: a meta-analysis of randomized controlled trials. PLoS One, 2011, 6: e26267

[19] Lewiecki EM. New and emerging concepts in the use of denosumab for the treatment of osteoporosis. Ther. Adv. Musculoskelet. Dis., 2018, 10: 209-223

[20] Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature, 2003, 423: 337-342

[21] Xie H et al. PDGF-BB secreted by preosteoclasts induces angiogenesis during coupling with osteogenesis. Nat. Med., 2014, 20: 1270-1278

[22] Kusumbe AP, Ramasamy SK, Adams RH. Coupling of angiogenesis and osteogenesis by a specific vessel subtype in bone. Nature, 2014, 507: 323-328

[23] Ramasamy SK, Kusumbe AP, Wang L, Adams RH. Endothelial Notch activity promotes angiogenesis and osteogenesis in bone. Nature, 2014, 507: 376-380

[24] Boissy P, Saltel F, Bouniol C, Jurdic P, Machuca-Gayet I. Transcriptional activity of nuclei in multinucleated osteoclasts and its modulation by calcitonin. Endocrinology, 2002, 143: 1913-1921

[25] Koga T et al. Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature, 2004, 428: 758-763

[26] Chung CH, Lin KT, Chang CH, Peng HC, Huang TF. The integrin alpha2beta1 agonist, aggretin, promotes proliferation and migration of VSMC through NF-kB translocation and PDGF production. Br. J. Pharm., 2009, 156: 846-856

[27] Au PY et al. The oncogene PDGF-B provides a key switch from cell death to survival induced by TNF. Oncogene, 2005, 24: 3196-3205

[28] Peng Y et al. Glucocorticoids disrupt skeletal angiogenesis through transrepression of NF-kappaB-mediated preosteoclast Pdgfb transcription in young mice. J. Bone Min. Res., 2020, 35: 1188-1202

[29] Lee SH et al. v-ATPase V0 subunit d2-deficient mice exhibit impaired osteoclast fusion and increased bone formation. Nat. Med., 2006, 12: 1403-1409

[30] Rochette L et al. The role of osteoprotegerin in vascular calcification and bone metabolism: the basis for developing new therapeutics. Calcif. Tissue Int., 2019, 105: 239-251

[31] Wang L et al. Human type H vessels are a sensitive biomarker of bone mass. Cell Death Dis., 2017, 8

[32] Dou C et al. Graphene-based MicroRNA transfection blocks preosteoclast fusion to increase bone formation and vascularization. Adv. Sci. (Weinh.), 2018, 5: 1700578

[33] Xu R et al. Targeting skeletal endothelium to ameliorate bone loss. Nat. Med., 2018, 24: 823-833

[34] Stewart SK. Fracture non-union: a review of clinical challenges and future research needs. Malays. Orthop. J., 2019, 13: 1-10

[35] Hankenson KD, Dishowitz M, Gray C, Schenker M. Angiogenesis in bone regeneration. Injury, 2011, 42: 556-561

[36] Deng AD, Innocenti M, Arora R, Gabl M, Tang JB. Vascularized small-bone transfers for fracture nonunion and bony defects. Clin. Plast. Surg., 2017, 44: 267-285

Funding

This research was partially supported by a grant from NextCure Inc.